PD98059

For research use only. Not for use in humans.

目录号：S1177

CAS No. 167869-21-8

PD98059 是一种非ATP竞争性的MEK抑制剂，无细胞试验中IC50为2 μM，特异性抑制MEK-1介导的MAPK激活；不直接抑制ERK1或ERK2。PD98059 是一种aryl hydrocarbon receptor (AHR)的配体并起到拮抗剂的功能。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 1099.68	现货
10mg	RMB 1213.08	现货
50mg	RMB 3845.73	现货
200mg	RMB 5489.52	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的PD98059发表文献401篇：

Immunity, 2021, S1074-7613(20)30538-0

PubMed: 33421362 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):798-815

PubMed: 31031016 ( click the link to review the publication )

Cancer Cell, 2019, 35(1):17-32

PubMed: 30645973 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(3):329-344

PubMed: 28089908 ( click the link to review the publication )

Cancer Cell, 2017, 32(6):840-855

PubMed: 29232556 ( click the link to review the publication )

Nature, 2016, 10.1038/nature19347

PubMed: 27580028 ( click the link to review the publication )

Cancer Cell, 2015,

PubMed: 25670080 ( click the link to review the publication )

Cancer Cell, 2014, 26(5):754-69

PubMed: 25446900 ( click the link to review the publication )

Mol Cell, 2021, S1097-2765(21)00269-0

PubMed: 33991485 ( click the link to review the publication )

Cell Rep, 2021, 35(13):109331

PubMed: 34192547 ( click the link to review the publication )

J Hazard Mater, 2021, 422:126850

PubMed: 34419847 ( click the link to review the publication )

Cell Death Dis, 2021, 12(4):344

PubMed: 33795637 ( click the link to review the publication )

Signal Transduct Target Ther, 2021, 6(1):333

PubMed: 34482361 ( click the link to review the publication )

Oncoimmunology, 2021, 10(1):1897295

PubMed: 33763295 ( click the link to review the publication )

Mol Oncol, 2021, 10.1002/1878-0261.12936

PubMed: 33675143 ( click the link to review the publication )

Front Cell Dev Biol, 2021, 9:694675

PubMed: 34336841 ( click the link to review the publication )

Int J Mol Sci, 2021, 22(9)4652

PubMed: 33925033 ( click the link to review the publication )

Ecotoxicol Environ Saf, 2021, 214:112080

PubMed: 33677380 ( click the link to review the publication )

mSphere, 2021, 6(1)e00986-20

PubMed: 33408225 ( click the link to review the publication )

Front Oncol, 2021, 11:621154

PubMed: 33718179 ( click the link to review the publication )

Front Microbiol, 2021, 12:713531

PubMed: 34394064 ( click the link to review the publication )

J Biol Chem, 2021, S0021-9258(21)00173-3

PubMed: 33571522 ( click the link to review the publication )

Cancer Cell Int, 2021, 21(1):302

PubMed: 34107979 ( click the link to review the publication )

Int J Biol Macromol, 2021, 180:129-142

PubMed: 33676979 ( click the link to review the publication )
Int J Pharm, 2021, 606:120876

PubMed: 34252520 ( click the link to review the publication )

J Gastroenterol Hepatol, 2021, 10.1111/jgh.15486

PubMed: 33694195 ( click the link to review the publication )

J Ethnopharmacol, 2021, 282:114582

PubMed: 34492322 ( click the link to review the publication )

J Agric Food Chem, 2021, 10.1021/acs.jafc.1c00199

PubMed: 33749262 ( click the link to review the publication )

J Immunol Res, 2021, 2021:8483938

PubMed: 34222497 ( click the link to review the publication )

Food Funct, 2021, 12(15):6755-6765

PubMed: 34116563 ( click the link to review the publication )

Int Immunopharmacol, 2021, 97:107628

PubMed: 34015701 ( click the link to review the publication )

Molecules, 2021, 26(8)2204

PubMed: 33921192 ( click the link to review the publication )

Int J Mol Med, 2021, 47(6)103

PubMed: 33907828 ( click the link to review the publication )

ACS Omega, 2021, 6(7):4759-4766

PubMed: 33644583 ( click the link to review the publication )

Int J Med Sci, 2021, 18(11):2251-2261

PubMed: 33967600 ( click the link to review the publication )

Pathol Oncol Res, 2021, 27:640936

PubMed: 34257606 ( click the link to review the publication )

Viruses, 2021, 13(6)1062

PubMed: 34205098 ( click the link to review the publication )

Biochem Pharmacol, 2021, 186:114479

PubMed: 33617842 ( click the link to review the publication )

J Ethnopharmacol, 2021, 270:113783

PubMed: 33421596 ( click the link to review the publication )

J Cell Physiol, 2021, 236(2):1375-1390

PubMed: 33128793 ( click the link to review the publication )

Am J Transl Res, 2021, 13(2):708-718

PubMed: 33594320 ( click the link to review the publication )

BMC Complement Med Ther, 2021, 21(1):128

PubMed: 33888116 ( click the link to review the publication )

Sci Adv, 2020, 22;6(21):eaaz5913

PubMed: 32494742 ( click the link to review the publication )

Cell Rep, 2020, 7;30(1):215-228 e5

PubMed: 31914388 ( click the link to review the publication )

Part Fibre Toxicol, 2020, 17(1):46

PubMed: 32948194 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-01453-2

PubMed: 32917954 ( click the link to review the publication )

Cancers (Basel), 2020, 12(10)E2795

PubMed: 33003386 ( click the link to review the publication )

Cancers (Basel), 2020, 12(11)E3216

PubMed: 33142778 ( click the link to review the publication )
Cell Death Dis, 2020, 11(2):143

PubMed: 32081857 ( click the link to review the publication )

Cell Death Dis, 2020, 14;11(4):230

PubMed: 32286266 ( click the link to review the publication )

Glia, 2020, 10.1002/glia.23790

PubMed: 32036619 ( click the link to review the publication )

FASEB J, 2020, 10.1096/fj.202000186RRR

PubMed: 32918765 ( click the link to review the publication )

Stem Cell Res Ther, 2020, 11(1):28

PubMed: 31964421 ( click the link to review the publication )

Oxid Med Cell Longev, 2020, 12;2020:6837982

PubMed: 32318240 ( click the link to review the publication )

Cell Oncol (Dordr), 2020, 10.1007/s13402-020-00554-0

PubMed: 32910411 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(11):3765-3783

PubMed: 33294266 ( click the link to review the publication )

Cancer Biol Med, 2020, 17(2):357-370

PubMed: 32587774 ( click the link to review the publication )

Chemosphere, 2020, 246:125774

PubMed: 31901531 ( click the link to review the publication )

J Cell Mol Med, 2020, 10.1111/jcmm.16135

PubMed: 33247550 ( click the link to review the publication )

Toxicol Sci, 2020, kfaa159

PubMed: 33078829 ( click the link to review the publication )

Int J Mol Sci, 2020, 16;21(10):E3527

PubMed: 32429376 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(4)

PubMed: 32074942 ( click the link to review the publication )

Microorganisms, 2020, 11;8(3) pii: E389

PubMed: 32168837 ( click the link to review the publication )

Am J Physiol Endocrinol Metab, 2020, 1;318(5):E613-E624

PubMed: 32154742 ( click the link to review the publication )

J Biol Chem, 2020, 295(3):673-689

PubMed: 31780563 ( click the link to review the publication )

Endocrinology, 2020, 161(12)bqaa190

PubMed: 33068422 ( click the link to review the publication )

Biomed Pharmacother, 2020, 23;128:110245

PubMed: 32454290 ( click the link to review the publication )

Biomed Pharmacother, 2020, 131:110724

PubMed: 32920518 ( click the link to review the publication )

Am J Physiol Heart Circ Physiol, 2020, 10.1152/ajpheart.00606.2020

PubMed: 33337962 ( click the link to review the publication )

Life Sci, 2020, 13;252:117666

PubMed: 32298737 ( click the link to review the publication )

Chem Biol Interact, 2020, 315:108910

PubMed: 31790661 ( click the link to review the publication )

Food Funct, 2020, 11(12):10968-10978

PubMed: 33283791 ( click the link to review the publication )
Int Immunopharmacol, 2020, 81:105979

PubMed: 31771816 ( click the link to review the publication )

Eur J Pharmacol, 2020, 868:172886

PubMed: 31866407 ( click the link to review the publication )

Exp Biol Med (Maywood), 2020, 245(1):21-33

PubMed: 31810383 ( click the link to review the publication )

Exp Biol Med (Maywood), 2020, 245(7):654-666

PubMed: 32075431 ( click the link to review the publication )

BMC Microbiol, 2020, 20(1):171

PubMed: 32560675 ( click the link to review the publication )

Environ Toxicol, 2020, 10.1002/tox.22942

PubMed: 32485087 ( click the link to review the publication )

Cardiovasc Drugs Ther, 2020, 10.1007/s10557-020-07117-3

PubMed: 33242203 ( click the link to review the publication )

Biochem Biophys Res Commun, 2020, 521(2):492-498

PubMed: 31677783 ( click the link to review the publication )

Onco Targets Ther, 2020, 2;13:2757-2769

PubMed: 32308411 ( click the link to review the publication )

Int J Gen Med, 2020, 13:1495-1507

PubMed: 33328759 ( click the link to review the publication )

Biomed Pharmacother, 2020, 121:109669

PubMed: 31766100 ( click the link to review the publication )

J Ethnopharmacol, 2020, S0378-8741(20)33532-7

PubMed: 33264660 ( click the link to review the publication )

Curr Eye Res, 2020, 10.1080/02713683

PubMed: 31951764 ( click the link to review the publication )

Sci Rep, 2020, 10(1):13124

PubMed: 32753665 ( click the link to review the publication )

Biochem Biophys Res Commun, 2020, 524(4):1064-1071

PubMed: 32070494 ( click the link to review the publication )

Neuroreport, 2020, 31(14):1007-1014

PubMed: 32815825 ( click the link to review the publication )

Transl Res, 2020, S1931-5244(20)30250-4

PubMed: 33129993 ( click the link to review the publication )

Brain Inj, 2020, 34(9):1277-1282

PubMed: 32749897 ( click the link to review the publication )

J Cell Mol Med, 2020, 10.1111/jcmm.15665

PubMed: 32705806 ( click the link to review the publication )

Bone, 2020, 141:115573

PubMed: 32768686 ( click the link to review the publication )

Genome Biol, 2020, 21(1):174

PubMed: 32669109 ( click the link to review the publication )

Am J Chin Med, 2020, 48(1):223-244

PubMed: 32054305 ( click the link to review the publication )

Oral Dis, 2020, 10.1111

PubMed: 32176411 ( click the link to review the publication )

Onco Targets Ther, 2020, 13:7165-7176

PubMed: 32801748 ( click the link to review the publication )
Anim Biotechnol, 2020, 1-13

PubMed: 32657254 ( click the link to review the publication )

Am J Transl Res, 2020, 12(7):3557-3576

PubMed: 32774719 ( click the link to review the publication )

J Cell Mol Med, 2020, 24(8):4480-4493

PubMed: 32168416 ( click the link to review the publication )

Drug Deliv Transl Res, 2020, 7

PubMed: 32378175 ( click the link to review the publication )

Nat Commun, 2019, 10(1-:1128

PubMed: 30850660 ( click the link to review the publication )

EMBO J, 2019, 38(12)

PubMed: 31068361 ( click the link to review the publication )

Dev Cell, 2019, 51(5):602-616.e12

PubMed: 31794718 ( click the link to review the publication )

Cancer Res, 2019, 10.1158/0008-5472.CAN-18-2486

PubMed: 31253668 ( click the link to review the publication )

Cancer Res, 2019, 10.1158/0008-5472.CAN-19-1555

PubMed: 31744816 ( click the link to review the publication )

BMC Med, 2019, 17(1):42

PubMed: 30782145 ( click the link to review the publication )

Oncogene, 2019, 38(49):7433-7446

PubMed: 31427736 ( click the link to review the publication )

EBioMedicine, 2019, 42:326-339

PubMed: 30879923 ( click the link to review the publication )

Antioxid Redox Signal, 2019, 31(12):804-818

PubMed: 31088299 ( click the link to review the publication )

Cancer Lett, 2019, 10.1016/j.canlet.2019.07.016

PubMed: 31352079 ( click the link to review the publication )

Emerg Microbes Infect, 2019, 8(1):934-945

PubMed: 31237474 ( click the link to review the publication )

Cancers (Basel), 2019, 11(1)E75

PubMed: 30641867 ( click the link to review the publication )

Free Radic Biol Med, 2019, 141:21-33

PubMed: 31167117 ( click the link to review the publication )

J Clin Med, 2019, 8(6)

PubMed: 31238539 ( click the link to review the publication )

FASEB J, 2019,

PubMed: 30458112 ( click the link to review the publication )

Cell Commun Signal, 2019, 17(1):75

PubMed: 31307477 ( click the link to review the publication )

Aging (Albany NY), 2019, 11(22):10610-10625

PubMed: 31785145 ( click the link to review the publication )

Cell Prolif, 2019, 52(3):e12575

PubMed: 30838710 ( click the link to review the publication )

Stem Cell Res Ther, 2019, 10(1):80

PubMed: 30849996 ( click the link to review the publication )

Stem Cell Res Ther, 2019, 10(1):350

PubMed: 31775870 ( click the link to review the publication )
Oxid Med Cell Longev, 2019, 2019:4546975

PubMed: 31049135 ( click the link to review the publication )

Pharmacol Res, 2019, 143:73-85

PubMed: 30862605 ( click the link to review the publication )

J Recept Signal Transduct Res, 2019, 39(2):175-186

PubMed: 31354091 ( click the link to review the publication )

J Cell Physiol, 2019, 234(11):20779-20789

PubMed: 31025337 ( click the link to review the publication )

J Cell Physiol, 2019, 234(4):4504-4514

PubMed: 30246502 ( click the link to review the publication )

J Cell Physiol, 2019, 234(6):8846-8861

PubMed: 30317597 ( click the link to review the publication )

Front Oncol, 2019, 9:1244

PubMed: 31799197 ( click the link to review the publication )

J Cell Mol Med, 2019, 23(2):920-933

PubMed: 30394679 ( click the link to review the publication )

Sci Rep, 2019, 9(1):840

PubMed: 30696869 ( click the link to review the publication )

Int J Biol Sci, 2019, 15(8):1685-1695

PubMed: 31360111 ( click the link to review the publication )

Front Microbiol, 2019,

PubMed: 32038504 ( click the link to review the publication )

J Biol Chem, 2019, 294(18):7221-7230

PubMed: 30846565 ( click the link to review the publication )

J Biol Chem, 2019, 294(9):3284-3293

PubMed: 30573683 ( click the link to review the publication )

Int J Biol Macromol, 2019, 135:212-225

PubMed: 31108149 ( click the link to review the publication )

Gene, 2019, 683:195-209

PubMed: 30340049 ( click the link to review the publication )

Inflammopharmacology, 2019, 27(3):561-571

PubMed: 30251233 ( click the link to review the publication )

Mar Drugs, 2019, 17(1)E36

PubMed: 30626153 ( click the link to review the publication )

Cancer Manag Res, 2019, 11:839-855

PubMed: 30697076 ( click the link to review the publication )

Cancer Manag Res, 2019, 11:2653-2661

PubMed: 31114328 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2019, 362:59-66

PubMed: 30352208 ( click the link to review the publication )

Cell Signal, 2019, 54:17-26

PubMed: 30471465 ( click the link to review the publication )

Biomed Pharmacother, 2019, 116:109032

PubMed: 31163381 ( click the link to review the publication )

J Cell Biochem, 2019, 120(8):12500-12507

PubMed: 30834595 ( click the link to review the publication )

Life Sci, 2019, 229:1-12

PubMed: 30910647 ( click the link to review the publication )
Phytother Res, 2019, 33(8):2102-2117

PubMed: 31209984 ( click the link to review the publication )

Exp Cell Res, 2019, 379(1):65-72

PubMed: 30898547 ( click the link to review the publication )

J Tissue Eng Regen Med, 2019, 13(4):625-636

PubMed: 30770650 ( click the link to review the publication )

Cell Cycle, 2019, 18(21):2928-2938

PubMed: 31496351 ( click the link to review the publication )

Chem Biol Interact, 2019, 310:108741

PubMed: 31299238 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2019, 145(2):411-427

PubMed: 30483898 ( click the link to review the publication )

Am J Transl Res, 2019, 11(9):5824-5835

PubMed: 31632551 ( click the link to review the publication )

Alcohol Clin Exp Res, 2019, 43(11):2344-2353

PubMed: 31498445 ( click the link to review the publication )

Int Immunopharmacol, 2019, 77:105955

PubMed: 31678866 ( click the link to review the publication )

Toxicol In Vitro, 2019, 56:156-162

PubMed: 30677511 ( click the link to review the publication )

Molecules, 2019, 24(6)

PubMed: 30901941 ( click the link to review the publication )

Molecules, 2019, 24(6)

PubMed: 30889805 ( click the link to review the publication )

Oncol Rep, 2019, 41(6):3292-3304

PubMed: 31002345 ( click the link to review the publication )

Free Radic Res, 2019, 53(3):348-358

PubMed: 30773942 ( click the link to review the publication )

Clin Res Hepatol Gastroenterol, 2019, 10.1016/j

PubMed: 31422034 ( click the link to review the publication )

Environ Toxicol, 2019, 34(6):679-688

PubMed: 30801954 ( click the link to review the publication )

Am J Reprod Immunol, 2019, 81(1):e13073

PubMed: 30461130 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 10.1016/j.bbrc.2019.11.110

PubMed: 31761326 ( click the link to review the publication )

Lipids Health Dis, 2019, 18(1):71

PubMed: 30909920 ( click the link to review the publication )

Biomed Res Int, 2019, 2019:3851718

PubMed: 30993112 ( click the link to review the publication )

Acta Biochim Biophys Sin (Shanghai), 2019, 51(10):1056-1063

PubMed: 31555794 ( click the link to review the publication )

Med Sci Monit, 2019, 25:6491-6503

PubMed: 31465316 ( click the link to review the publication )

Med Sci Monit, 2019, 25:7666-7674

PubMed: 31605603 ( click the link to review the publication )

Cell Biochem Biophys, 2019, 77(4):367-377

PubMed: 31659617 ( click the link to review the publication )
Cell Reprogram, 2019, 21(5):238-248

PubMed: 31369321 ( click the link to review the publication )

Life Sci, 2019, 235:116863

PubMed: 31513817 ( click the link to review the publication )

Biosci Rep, 2019, 39(11)

PubMed: 31548362 ( click the link to review the publication )

Cancers (Basel), 2019, 11(6)E840

PubMed: 31216681 ( click the link to review the publication )

Toxicol Lett, 2019, 301:98-107

PubMed: 30481581 ( click the link to review the publication )

Commun Biol, 2019, 2:359

PubMed: 31602408 ( click the link to review the publication )

Biochim Biophys Acta Gene Regul Mech, 2019, 1862(8):846-857

PubMed: 31054961 ( click the link to review the publication )

Am J Chin Med, 2019, 913-931

PubMed: 31096773 ( click the link to review the publication )

Am J Respir Crit Care Med, 2019, 200(5):617-627

PubMed: 30817168 ( click the link to review the publication )

Nutrients, 2019, 11(4)E782

PubMed: 30987344 ( click the link to review the publication )

Genes Dev, 2018, 32(5-6):448-461

PubMed: 29567766 ( click the link to review the publication )

Elife, 2018, 7

PubMed: 29595474 ( click the link to review the publication )

Oncogene, 2018,

PubMed: 29059160 ( click the link to review the publication )

Oncogene, 2018, 37(24):3275-3289

PubMed: 29551771 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 37(1):113

PubMed: 29866133 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 17;37(1):8

PubMed: 29343273 ( click the link to review the publication )

Cancers (Basel), 2018, 10(11)E439

PubMed: 30441794 ( click the link to review the publication )

Cell Death Dis, 2018, 9(12):1140

PubMed: 30442927 ( click the link to review the publication )

Cell Death Dis, 2018, 9(3):278

PubMed: 29449539 ( click the link to review the publication )

Cell Death Dis, 2018, 9(11):1052

PubMed: 30323190 ( click the link to review the publication )

Br J Cancer, 2018, 119(9):1094-1105

PubMed: 30401978 ( click the link to review the publication )

Front Immunol, 2018, 9:2033

PubMed: 30283437 ( click the link to review the publication )

Mol Oncol, 2018, 12(2):224-238

PubMed: 29193645 ( click the link to review the publication )

Hum Reprod, 2018, 33(11):2096-2106

PubMed: 30272163 ( click the link to review the publication )
J Cancer, 2018, 9(23):4449-4462

PubMed: 30519351 ( click the link to review the publication )

Biochim Biophys Acta Mol Cell Biol Lipids, 2018, 1863(2):177-190

PubMed: 29217477 ( click the link to review the publication )

Oxid Med Cell Longev, 2018, 2018:4572893

PubMed: 30538801 ( click the link to review the publication )

Biochim Biophys Acta Mol Cell Res, 2018, 1865(1):57-66

PubMed: 28964848 ( click the link to review the publication )

J Virol, 2018, 92(8)

PubMed: 29386287 ( click the link to review the publication )

J Cell Mol Med, 2018, 22(7):3340-3352

PubMed: 29566307 ( click the link to review the publication )

Sci Rep, 2018, 8(1-:10070

PubMed: 29968778 ( click the link to review the publication )

Sci Rep, 2018, 8(1):3120

PubMed: 29449636 ( click the link to review the publication )

Stem Cells Int, 2018, 2018:9793845

PubMed: 30693038 ( click the link to review the publication )

Inflammopharmacology, 2018, 10.1007/s10787-018-0492-y

PubMed: 29748880 ( click the link to review the publication )

Cell Mol Neurobiol, 2018, 38(3):627-633

PubMed: 28608000 ( click the link to review the publication )

Biomed Pharmacother, 2018, 105:320-325

PubMed: 29864620 ( click the link to review the publication )

Biomed Pharmacother, 2018, 105:282-289

PubMed: 29860220 ( click the link to review the publication )

Tissue Eng Part A, 2018, 24(5-6):502-515

PubMed: 28602124 ( click the link to review the publication )

J Cell Biochem, 2018, 119(1):300-313

PubMed: 28569433 ( click the link to review the publication )

Chem Res Toxicol, 2018, 31(2):127-136

PubMed: 29156121 ( click the link to review the publication )

J Agric Food Chem, 2018, 66(41):10721-10728

PubMed: 30257559 ( click the link to review the publication )

Front Physiol, 2018, 9:765

PubMed: 29977209 ( click the link to review the publication )

Cell Adh Migr, 2018, 12(2):109-117

PubMed: 25588050 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2018, 144(8):1487-1501

PubMed: 29858683 ( click the link to review the publication )

Toxicology, 2018, 408:62-69

PubMed: 29981841 ( click the link to review the publication )

Am J Transl Res, 2018, 10(8):2555-2566

PubMed: 30210692 ( click the link to review the publication )

Cancer Med, 2018,

PubMed: 29239135 ( click the link to review the publication )

Biochimie, 2018, 152:43-52

PubMed: 29960031 ( click the link to review the publication )
Molecules, 2018,

PubMed: 30513793 ( click the link to review the publication )

Oncol Rep, 2018, 40(1):29-38

PubMed: 29749533 ( click the link to review the publication )

Oncol Rep, 2018, 40(2):775-782

PubMed: 29901173 ( click the link to review the publication )

Ann Hematol, 2018, 97(4):641-654

PubMed: 29350259 ( click the link to review the publication )

Neurochem Res, 2018, 43(10-:1963-1977

PubMed: 30136162 ( click the link to review the publication )

PLoS One, 2018, 13(9):e0203402

PubMed: 30192802 ( click the link to review the publication )

PLoS One, 2018, 13(5):e0197422

PubMed: 29763460 ( click the link to review the publication )

PLoS One, 2018, 13(7):e0200878

PubMed: 30048489 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 496(4):1291-1295

PubMed: 29412164 ( click the link to review the publication )

Cell Biochem Funct, 2018, 36(3):155-165

PubMed: 29441602 ( click the link to review the publication )

Cell Biol Int, 2018, 42(5):598-607

PubMed: 29345412 ( click the link to review the publication )

Oncol Lett, 2018, 15(5):7443-7449

PubMed: 29731895 ( click the link to review the publication )

Oncol Lett, 2018, 15(6):8442-8446

PubMed: 29805580 ( click the link to review the publication )

In Vivo, 2018, 32(3):549-554

PubMed: 29695559 ( click the link to review the publication )

In Vivo, 2018, 32(6):1361-1368

PubMed: 30348689 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 37(1):115

PubMed: 29866191 ( click the link to review the publication )

J Agric Food Chem, 2018, 66(31):8307-8318

PubMed: 29961319 ( click the link to review the publication )

Sci Total Environ, 2018, 643:496-506

PubMed: 29945085 ( click the link to review the publication )

J Clin Invest, 2017, 127(1):153-168

PubMed: 27893461 ( click the link to review the publication )

Nat Commun, 2017, 8:15776

PubMed: 28585539 ( click the link to review the publication )

Dev Cell, 2017, 41(5):527-539.e5

PubMed: 28586645 ( click the link to review the publication )

Oncogene, 2017, 36(46):6359-6373

PubMed: 28745319 ( click the link to review the publication )

Antioxid Redox Signal, 2017, 27(2):73-92

PubMed: 27650197 ( click the link to review the publication )

Cancer Lett, 2017, 395:31-44

PubMed: 28268166 ( click the link to review the publication )
Cancer Lett, 2017, 401:1-10

PubMed: 28483515 ( click the link to review the publication )

PLoS Pathog, 2017, 13(4):e1006321

PubMed: 28394926 ( click the link to review the publication )

Cell Physiol Biochem, 2017, 41(5):1957-1969

PubMed: 28391263 ( click the link to review the publication )

Mol Cell Proteomics, 2017, 16(9):1694-1704

PubMed: 28674151 ( click the link to review the publication )

J Neurochem, 2017, 142(2):231-245

PubMed: 28444734 ( click the link to review the publication )

Sci Rep, 2017, 7:43242

PubMed: 28266583 ( click the link to review the publication )

Sci Rep, 2017, 7(1):13319

PubMed: 29042627 ( click the link to review the publication )

Sci Rep, 2017, 7(1):1663

PubMed: 28490734 ( click the link to review the publication )

J Steroid Biochem Mol Biol, 2017, 171:318-327

PubMed: 28529129 ( click the link to review the publication )

Endocrinology, 2017, 158(10):3281-3291

PubMed: 28651331 ( click the link to review the publication )

Immunol Cell Biol, 2017, 95(10):943-952

PubMed: 28878297 ( click the link to review the publication )

Biomed Pharmacother, 2017, 89:1037-1044

PubMed: 28292012 ( click the link to review the publication )

Biomed Pharmacother, 2017, 87:332-341

PubMed: 28064106 ( click the link to review the publication )

Brain Res Bull, 2017, 130:236-244

PubMed: 28189515 ( click the link to review the publication )

Exp Cell Res, 2017, 360(2):281-291

PubMed: 28919123 ( click the link to review the publication )

Chem Biol Interact, 2017, 270:1-8

PubMed: 28390675 ( click the link to review the publication )

Am J Transl Res, 2017, 9(6):2878-2890

PubMed: 28670376 ( click the link to review the publication )

Dev Comp Immunol, 2017, 76:392-402

PubMed: 28713009 ( click the link to review the publication )

Oncol Rep, 2017, 38(1):591-597

PubMed: 28560404 ( click the link to review the publication )

Oncol Rep, 2017, 37(2):1036-1044

PubMed: 28000898 ( click the link to review the publication )

Int J Mol Med, 2017, 39(1):217-222

PubMed: 27878250 ( click the link to review the publication )

Spine (Phila Pa 1976), 2017, 42(2):E61-E70

PubMed: 27270637 ( click the link to review the publication )

Neurochem Res, 2017, 10.1007/s11064-017-2174-3

PubMed: 28083849 ( click the link to review the publication )

PLoS One, 2017, 12(12):e0189920

PubMed: 29261770 ( click the link to review the publication )
Onco Targets Ther, 2017, 10:627-643

PubMed: 28223821 ( click the link to review the publication )

J Neurol Sci, 2017, 372:171-177

PubMed: 28017206 ( click the link to review the publication )

DNA Cell Biol, 2017, 36(11):1029-1038

PubMed: 28945461 ( click the link to review the publication )

Exp Dermatol, 2017, 26(5):409-415

PubMed: 27762043 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 492(2):206-211

PubMed: 28821432 ( click the link to review the publication )

Food Nutr Res, 2017, 61(1):1368321

PubMed: 28970779 ( click the link to review the publication )

Microb Pathog, 2017, 10.1016/j.micpath

PubMed: 28131949 ( click the link to review the publication )

Cell Biochem Funct, 2017, 35(5):278-286

PubMed: 28749079 ( click the link to review the publication )

Cell Biol Int, 2017, 41(12):1307-1315

PubMed: 28816402 ( click the link to review the publication )

Evid Based Complement Alternat Med, 2017, 2017:5985703

PubMed: 28167972 ( click the link to review the publication )

J Asthma, 2017, 54(5):467-475

PubMed: 27905842 ( click the link to review the publication )

Mol Med Rep, 2017, 16(2):1445-1450

PubMed: 29067463 ( click the link to review the publication )

Mol Med Rep, 2017, 16(2):1417-1424

PubMed: 28627644 ( click the link to review the publication )

Poult Sci, 2017, 96(9):3043-3051

PubMed: 28431078 ( click the link to review the publication )

Oncotarget, 2017, 8(35):58417-58429

PubMed: 28938567 ( click the link to review the publication )

Drug Discov Ther, 2017, 11(4):212-217

PubMed: 28867754 ( click the link to review the publication )

Cell Prolif, 2017, 50(1)

PubMed: 27790820 ( click the link to review the publication )

Anesthesiology, 2017, 126(5):868-881

PubMed: 28121635 ( click the link to review the publication )

Oncotarget, 2017, 8(55):93878-93898

PubMed: 29212196 ( click the link to review the publication )

Oncotarget, 2017, 8(15):24237-24249

PubMed: 27458161 ( click the link to review the publication )

Menopause, 2017, 24(4):437-451

PubMed: 27922937 ( click the link to review the publication )

Oncotarget, 2017, 8(33):55084-55093

PubMed: 28903404 ( click the link to review the publication )

Pflugers Arch, 2017, 469(9):1061-1071

PubMed: 28455747 ( click the link to review the publication )

Clin Cancer Res, 2016, 10.1158/1078-0432.CCR-15-2242

PubMed: 27297582 ( click the link to review the publication )
Cell Mol Immunol, 2016, 13(4):524-34

PubMed: 26166769 ( click the link to review the publication )

Cell Mol Immunol, 2016, 13(5):640-50

PubMed: 27593484 ( click the link to review the publication )

Br J Dermatol, 2016, 175(6):1221-1231

PubMed: 27145925 ( click the link to review the publication )

Cell Death Dis, 2016, 7(10):e2435

PubMed: 27787522 ( click the link to review the publication )

Cell Death Dis, 2016, 7(10):e2412

PubMed: 27735943 ( click the link to review the publication )

Stem Cells, 2016, 34(11):2744-2757

PubMed: 27340942 ( click the link to review the publication )

Cell Physiol Biochem, 2016, 39(4):1317-28

PubMed: 27606810 ( click the link to review the publication )

Mol Oncol, 2016, 10(6):775-88

PubMed: 26842883 ( click the link to review the publication )

Neoplasia, 2016, 18(7):425-35

PubMed: 27435925 ( click the link to review the publication )

Oxid Med Cell Longev, 2016, 2016:2572175

PubMed: 26962394 ( click the link to review the publication )

Am J Cancer Res, 2016, 6(2):509-21

PubMed: 27186420 ( click the link to review the publication )

J Transl Med, 2016, 14:46

PubMed: 26861698 ( click the link to review the publication )

J Ethnopharmacol, 2016, 193:293-302

PubMed: 27553977 ( click the link to review the publication )

Prostate, 2016, 76(3):273-85

PubMed: 26499308 ( click the link to review the publication )

Exp Cell Res, 2016, 345(1):82-92

PubMed: 27237094 ( click the link to review the publication )

Int J Biochem Cell Biol, 2016, 80:132-142

PubMed: 27702651 ( click the link to review the publication )

Exp Eye Res, 2016, 145:456-467

PubMed: 26432918 ( click the link to review the publication )

Cell Immunol, 2016, 310:63-70

PubMed: 27687530 ( click the link to review the publication )

Inflamm Res, 2016, 65(3):193-202

PubMed: 26621504 ( click the link to review the publication )

Int J Mol Med, 2016, 38(4):1125-34

PubMed: 27599586 ( click the link to review the publication )

Neurochem Res, 2016, 41(7):1635-44

PubMed: 26961889 ( click the link to review the publication )

PLoS One, 2016, 11(1):e0146554

PubMed: 26752289 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 474(2):330-7

PubMed: 27107695 ( click the link to review the publication )

Mol Med Rep, 2016, 14(2):1430-8

PubMed: 27278862 ( click the link to review the publication )
Pharm Biol, 2016, 54(10):2220-35

PubMed: 27049854 ( click the link to review the publication )

Exp Ther Med, 2016, 11(6):2413-2419

PubMed: 27284329 ( click the link to review the publication )

Oncotarget, 2016, 7(19):27874-88

PubMed: 27036049 ( click the link to review the publication )

Sci Rep, 2016, 6:30121

PubMed: 27444207 ( click the link to review the publication )

Oncotarget, 2016, 7(28):43442-43460

PubMed: 27259276 ( click the link to review the publication )

Toxicol Res (Camb), 2016, 5(6):1573-1584

PubMed: 30090458 ( click the link to review the publication )

Tumour Biol, 2016, 37(8):10257-67

PubMed: 26831668 ( click the link to review the publication )

Tumour Biol, 2016, 37(3):3727-38

PubMed: 26468015 ( click the link to review the publication )

Oncotarget, 2016, 7(30):48501-48516

PubMed: 27384485 ( click the link to review the publication )

Oncotarget, 2016, 7(16):22623-31

PubMed: 26980707 ( click the link to review the publication )

Pflugers Arch, 2016, 468(11-12):2041-2051

PubMed: 27592222 ( click the link to review the publication )

Oncotarget, 2016, 7(37):59236-59244

PubMed: 27494860 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27322144 ( click the link to review the publication )

Nat Commun, 2015, 10.1038/ncomms9390

PubMed: 26399630 ( click the link to review the publication )

Nat Commun, 2015, 6:8481

PubMed: 26412466 ( click the link to review the publication )

Mol Nutr Food Res, 2015, 59(12):2471-9

PubMed: 26331632 ( click the link to review the publication )

Am J Cancer Res, 2015, 5(9):2660-72

PubMed: 26609474 ( click the link to review the publication )

Mol Cancer Res, 2015, 13(12):1578-90

PubMed: 26376801 ( click the link to review the publication )

J Transl Med, 2015, 13(1):42

PubMed: 25638174 ( click the link to review the publication )

Sci Rep, 2015, 5:18314

PubMed: 26658818 ( click the link to review the publication )

J Nat Prod, 2015, 78(7):1689-96

PubMed: 26171689 ( click the link to review the publication )

Cytokine, 2015, 17:139-144

PubMed: ( click the link to review the publication )

Cytokine, 2015, 71(2):139-44

PubMed: 25461391 ( click the link to review the publication )

J Orthop Res, 2015, 10.1002/jor.22830

PubMed: 25731708 ( click the link to review the publication )
Arch Biochem Biophys, 2015, 585:10-16

PubMed: 26363213 ( click the link to review the publication )

Toxicol In Vitro, 2015, 30(1 Pt B):521-8

PubMed: 26363202 ( click the link to review the publication )

Neurochem Res, 2015, 40(8):1609-19

PubMed: 26088686 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0122109

PubMed: 25853521 ( click the link to review the publication )

Biochem Biophys Res Commun, 2015, 463(4):612-7

PubMed: 26043686 ( click the link to review the publication )

Exp Biol Med, 2015, 10.1177/1535370215576312

PubMed: 25767191 ( click the link to review the publication )

Leuk Res, 2015, 10.1016/j.leukres.2015.08.007

PubMed: 26346348 ( click the link to review the publication )

J Cardiovasc Pharmacol, 2015, 66(3):285-93

PubMed: 25955575 ( click the link to review the publication )

Acta Biochim Biophys Sin, 2015, 47(7), 1–9

PubMed: 26071572 ( click the link to review the publication )

Cell Biochem Funct, 2015, 33(3):134-42

PubMed: 25753185 ( click the link to review the publication )

Evid Based Complement Alternat Med, 2015, 2015:307594

PubMed: 25802536 ( click the link to review the publication )

Tissue Cell, 2015, 47(3):301-10

PubMed: 25958163 ( click the link to review the publication )

Growth Factors, 2015, 33(5-6):356-65

PubMed: 26607681 ( click the link to review the publication )

Genet Mol Res, 2015, 14(4):18325-33

PubMed: 26782480 ( click the link to review the publication )

EMBO Mol Med, 2014, 6(6):821-34

PubMed: 24778454 ( click the link to review the publication )

Br J Pharmacol, 2014, 171(24):5757-73

PubMed: 25117211 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1428

PubMed: 25275589 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1187

PubMed: 24743742 ( click the link to review the publication )

FASEB J, 2014, 10.1096/fj.13-247924

PubMed: 24903273 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(4):926-37

PubMed: 24482380 ( click the link to review the publication )

Carcinogenesis, 2014, 35(4):795-806

PubMed: 24265293 ( click the link to review the publication )

Thromb Haemost, 2014, 112(5):992-1001

PubMed: 25057055 ( click the link to review the publication )

Cell Microbiol, 2014, 16(9):1441-55

PubMed: 24779413 ( click the link to review the publication )

Biomed Pharmacother, 2014, 68(8):1037-43

PubMed: 25312822 ( click the link to review the publication )
Chem Res Toxicol, 2014, 27(9):1575-85

PubMed: 25148906 ( click the link to review the publication )

Life Sci, 2014, 108(2):63-70

PubMed: 24857982 ( click the link to review the publication )

Toxicol Lett, 2014, 226(1):81-9

PubMed: 24495410 ( click the link to review the publication )

Am J Physiol Renal Physiol, 2014, 307(1):F75-85

PubMed: 24872318 ( click the link to review the publication )

Oncol Rep, 2014, 32(6):2777-88

PubMed: 25335112 ( click the link to review the publication )

J Periodontal Res, 2014, 10.1111/jre.12193

PubMed: 24854880 ( click the link to review the publication )

PLoS One, 2014, 9(3):e85705

PubMed: 24633332 ( click the link to review the publication )

PLoS One, 2014, 9(1):e87311

PubMed: 24489893 ( click the link to review the publication )

PLoS One, 2014, 9(5):e94753

PubMed: 24787138 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 455(3-4):256-61

PubMed: 25449280 ( click the link to review the publication )

Biochem Biophy Res Co, 2014, 10.1016/j.bbrc.2014.11.002

PubMed: ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 446(1):167-72

PubMed: 24582558 ( click the link to review the publication )

J Cardiovasc Pharmacol, 2014, 64(2):180-90

PubMed: 24705173 ( click the link to review the publication )

Evid Based Complement Alternat Med, 2014, Zhang JL

PubMed: ( click the link to review the publication )

Oncol Lett, 2014, 8(4):1739-1744

PubMed: 25202402 ( click the link to review the publication )

Regul Pept, 2014, 194-195:41-8

PubMed: 25450576 ( click the link to review the publication )

Hepatology, 2013, 59(4):1262-72

PubMed: 23929627 ( click the link to review the publication )

Mol Cancer Ther, 2013, 13(1):37-48

PubMed: 24233399 ( click the link to review the publication )

Mol Cell Proteomics, 2013, 12(10):2952-68

PubMed: 23828894 ( click the link to review the publication )

J Thromb Haemost, 2013, 12(3):395-408

PubMed: 24354620 ( click the link to review the publication )

Biomolecules, 2013, 3(3):351-368

PubMed: 24619572 ( click the link to review the publication )

J Steroid Biochem Mol Biol, 2013, 144PA:223-227

PubMed: 24514755 ( click the link to review the publication )

Mol Cell Endocrinol, 2013, 375(1-2):89-96

PubMed: 23707617 ( click the link to review the publication )

Cell Signal, 2013, 26(3):512-20

PubMed: 24308969 ( click the link to review the publication )
Microbes Infect, 2013, 15(2):105-14

PubMed: 23164610 ( click the link to review the publication )

PLoS One, 2013, 8(12):e82610

PubMed: 24340049 ( click the link to review the publication )

PLoS One, 2013, 8(8): e70732

PubMed: 23967093 ( click the link to review the publication )

PLoS One, 2013, 8(2):e56735

PubMed: 23468877 ( click the link to review the publication )

PLoS One, 2013, 8(12):e85032

PubMed: 24376862 ( click the link to review the publication )

PLoS One, 2013, 8(5):e63890

PubMed: 23667687 ( click the link to review the publication )

Biochem Biophys Res Commun, 2013, 429(3-4):156-62

PubMed: 23142594 ( click the link to review the publication )

Cancer Cell Biology, 2013, 134(11):2560-71

PubMed: 24374738 ( click the link to review the publication )

J Genet Syndr Gene Ther, 2013, 4

PubMed: 25520884 ( click the link to review the publication )

Genetic Syndromes & Gene Therapy, 2013, 4:6

PubMed: ( click the link to review the publication )

J Natl Cancer Inst, 2012, 104(21):1673-9

PubMed: 22997239 ( click the link to review the publication )

J Biomol Screen, 2012, 17(6):813-21

PubMed: 22453235 ( click the link to review the publication )

Microbiol Immunol, 2012, 56(11):782-8

PubMed: 22938101 ( click the link to review the publication )

Sci Signal, 2011, 4(192):ra62

PubMed: 21954288 ( click the link to review the publication )

Atheroscler, 2011, 218(2):486-92

PubMed: 21782178 ( click the link to review the publication )

Int J Mol Med, 2011, 28(1):115-9

PubMed: 21455558 ( click the link to review the publication )

J Biol Chem, 2010, 285(43):32824-33

PubMed: 20729213 ( click the link to review the publication )

产品安全说明书

MEK抑制剂选择性比较

生物活性

产品描述

特性

PD98059不会抑制已经被c-Raf磷酸化的 MEK1

靶点

AhR ^[1] (Cell-free assay)	MEK1 ^[1] (Cell-free assay)
1 μM	2 μM

体外研究

PD98059 要么抑制本底的MEK1，要么抑制一种被部分激活的MEK突变体，该突变体是 218 和 222号位上丝氨酸突变为谷氨酸后形成的(MEK-2E)， IC50 为2 μM. PD98059 不会抑制JNK和P38这两个 MAPK 的同系物. PD98059会高度选择性的抑制MEK, 因为对其它包括Raf 激酶, cAMP-依赖性激酶, 蛋白激酶C, v-Src, 表皮生长因子 (EGF) 受体激酶, 胰岛素受体激酶, PDGF 受体激酶, 和磷脂酰肌醇(-3)激酶等在内的一系列激酶都没有抑制性。 PD98059 会抑制经过PDGF刺激而活化的MAPK 和胸苷进入 3T3 细胞， IC50分别为 ~10 μM 和 ~7 μM ^[1]。PD98059可以有效地阻止 MEK1 被Raf 或者MEK 激酶活化， IC50为4 μM, 可以微弱地抑制MEK2被 Raf 活化， IC50 为50 μM。在KB 和 PC12 细胞中, PD98059 不会抑制MKK4 和RK激酶这两个参与压力和白细胞介素-1介导的激酶级联反应的MEK的同系物的活化，在Swiss 3T3 细胞中也不会通过胰岛素或者表皮生长因子抑制p70 S6 激酶的活化^[2]。PD98059会在不改变细胞生存能力的情况下完全阻断神经生长因子(NGF)诱导的 PC12 细胞的分化^[3] 。PD98059会以剂量依赖性的方式抑制培养在含有破骨细胞分化因子培养基中的 RAW264.7细胞的增值，进而导致TRAP阳性细胞数量明显下降^[6]。

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
A2780	NXH2dVc3TnWwY4Tpc44hSXO\|YYm=	NUK0dmxtOjEEoN88US=>	M1;1TlEhcA>?		NYjTNWRU[myxY3vzJGRVS0RvaX7keYNm\CCGUkWg[ZhxemW\|c3nvci=>	M2K5SVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|Nkm2PFYzLz5{M{[5Olg3OjxxYU6=
AML 1#	MoLnRZBweHSxc3nzJGF{e2G7	NYHkbmNYOjEEoN88US=>	M2DGRVEzKGh?		M3;XVoVvcGGwY3XzJINmdGxiYYDvdJRwe2m\|IHnu[JVk\WRiYomgV\|E>	Mn\GQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5ME[2PVEoRjJ\|N{C2OlkyRC:jPh?=
KG-1	NYHHbldKSXCxcITvd4l{KEG\|c3H5	NVK0VG9XOjEEoN88US=>	NUG1[3JsOTJiaB?=		MUHlcohidmOnczDj[YxtKGGyb4D0c5NqeyCrbnT1Z4VlKGK7IGOx	M3TIUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{C2OlkyLz5{M{ewOlY6OTxxYU6=
HUVECs	NVHUbZRQSXCxcITvd4l{KEG\|c3H5	MXSyM\|Qh\|ryP	NHfKToEzPC92ODDo		NV\Qflh3cW6mdXPld{Bk\WyuIHTlZZRp	NXfye\|lHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3NFc2OjBpPkKzO\|A4PTJyPD;hQi=>
HepG2	NID4VpZHfW6ldHnvckBCe3OjeR?=	NWHPPVZVOjEEoN88US=>	NXW3XGJ3OjRiaB?=		NXTySYJrcW6qaXLpeJMhfGinIFjPMVEheHKxdHXpckBmgHC{ZYPzbY9vKGOxLYTy[YF1\WRid3n0bEBu\XSob4LtbY4>	MmO3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5MEe2NFkoRjJ\|N{C3OlA6RC:jPh?=
NB4	NVHGZo1LSXCxcITvd4l{KEG\|c3H5	NX\tTYY2OTBxMkCvOlAh\|ryP	NGDwUZkyNjViaB?=	NWX2RYRTTE2VTx?=	NVLh[HpY\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JINwNXS{ZXH0[YQhf2m2aDDQZYNtcXSjeHXs	MlLnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5M{W1OFEoRjJ\|N{O1OVQyRC:jPh?=
BxPC-3 cells	NX7SbWlvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYCyNOKh\|ryP	MlPXNE42KGh?		MWTpcohq[mm2czDWSWdHNUFvcnXneYxifGWmIFjVWmVEKGe{b4f0bEBidmRidIXi[UBnd3KvYYTpc44hcW6mdXPl[EBjgSCSQWKtNkBCWA>?	NUe3[2RZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3OlQxPDZpPkKzO\|Y1ODR4PD;hQi=>
MKN45	MVjBdI9xfG:\|aYOgRZN{[Xl?	NWDsW\|NTOTBizszNxsA>	NX7QSm9zOjRiaB?=		MmnQbY5kemWjc3XzJJRp\SCGQWDUMYlv\HWlZXSgZ4VtdCCjcH;weI9{cXN?	Ml3OQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5OUK1PFgoRjJ\|N{myOVg5RC:jPh?=
SGC7901	NF31OZRCeG:ydH;zbZMhSXO\|YYm=	MYixNEDPxE4EoB?=	MoTTNlQhcA>?		NETUXZRqdmO{ZXHz[ZMhfGinIFTBVHQucW6mdXPl[EBk\WyuIHHwc5B1d3Orcx?=	M3Ltc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{myOVg5Lz5{M{e5NlU5QDxxYU6=
MKN45	NF;xeVBHfW6ldHnvckBCe3OjeR?=	MX2xNEDPxE4EoB?=	NVrvRW9sOjRiaB?=		NWThRZc6cW6qaXLpeJMhfGinIHX4dJJme3Orb36gc4YheGixc4Doc5J6dGG2ZXSgSXJMOS9{	Mn\HQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5OUK1PFgoRjJ\|N{myOVg5RC:jPh?=
SGC7901	Mnr0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYe5eXBROTBizszNxsA>	NVe4RlU6OjRxNEivO\|IhcA>?		NUTTXHJxcW6qaXLpeJMh[2WubDDndo94fGhiY3:teJJm[XSnZDD3bZRpKESDUGS=	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd7MkW4PEc,OjN5OUK1PFg9N2F-
MKN45	Mo\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1r1UlExKM7:TdMg	NIL1dVQzPC92OD:3NkBp		MWTpcohq[mm2czDj[YxtKGe{b4f0bEBkdy22cnXheIVlKHerdHigSGFRXA>?	NF7DPXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{e5NlU5QCd-MkO3PVI2QDh:L3G+
SGC7901	M3L2Z2Z2dmO2aX;uJGF{e2G7	M4\YN\|ExKM7:TdMg	MoPpNlQhcA>?		MkK2bY5pcWKrdIOgeIhmKGW6cILld5Nqd25ib3[gdIhwe3Cqb4L5cIF1\WRiRWLLNU8z	MkGzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5OUK1PFgoRjJ\|N{myOVg5RC:jPh?=
HUASMCs	NYLsVoVsTnWwY4Tpc44hSXO\|YYm=	M2HiVFExKM7:TdMg	NF6zT48zPCCq		NU[0Vo05\GmvaX7pd4hmeyCDbnegTWku[2G3c3XkJHNQS1N\|IH3SUmEh[W6mIIDyc5RmcW5iZYjwdoV{e2mxbtMg	MmjvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6MU[0OlgoRjJ\|OEG2OFY5RC:jPh?=
HUASMCs	M{LMfmZ2dmO2aX;uJGF{e2G7	M4\Md\|ExKM7:TdMg	NXLCOXRNOjRiaB?=		MnzGbY5pcWKrdIOgRY5oKEmLLXnu[JVk\WRiRWLLNU8zKHCqb4PwbI9zgWyjdHnvckBt\X[nbB?=	Mo\lQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6MU[0OlgoRjJ\|OEG2OFY5RC:jPh?=
EPOR/CR3	M3P6eWZ2dmO2aX;uJGF{e2G7	Mo[4OVDDqM7:TR?=	MlW3N{Bp		M{Hlc5Jm\HWlZYOgSXBQKGGwZD;vdkBKVC1\|LXnu[JVk\WRidHjlJJR6em:\|aX7lJJBpd3OyaH;yfYxifGmxbtMg	NEP1SG09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{iyNFc{OSd-MkO4NlA4OzF:L3G+
NB4	M{nIcGZ2dmO2aX;uJGF{e2G7	NHi3SWMyOCEQvF5CpC=>	NVXr[pdPPzJiaB?=	NGHDVJFFVVOR	NX31WmNqcW6qaXLpeJMh\GG\|YYTpcoljNWmwZIXj[YQhS0RzMXKg[ZhxemW\|c3nvci=>	NYL6[GdSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4NlU2QDVpPkKzPFI2PTh3PD;hQi=>
HL60	MnXkSpVv[3Srb36gRZN{[Xl?	NHPsPYUzOMLizszN	NWPkWZU3PzJiaB?=	MWTEUXNQ	M3fSfIlvcGmkaYTzJIRie2G2aX7pZk1qdmS3Y3XkJGNFOTGkIHX4dJJme3Orb36=	NH\4NVQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{iyOVU5PSd-MkO4NlU2QDV:L3G+
HUVECs	M1y5d2Z2dmO2aX;uJGF{e2G7	NVnGbVEzOjVizszN	MVyxJIg>		MVPpcoNz\WG\|ZTDOSk3PwkJicE[1JI52[2ynYYKgeJJidnOub3PheIlwdg>?	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzlyMUCwPEc,OjN7MEGwNFg9N2F-
LNCaP	NEn3OGxHfW6ldHnvckBCe3OjeR?=	NVLoeJFmOTBizszNxsA>	M4PSVlEhcA>?		M{T5bIRm[3KnYYPld{B1cGViRVfGJJVxemWpdXzheIVlKHBvWVKtNS=>	NFS4fIw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{izPFMyQCd-MkO4N\|g{OTh:L3G+
HL-60	M33mTWFxd3C2b4Ppd{BCe3OjeR?=	NF;ZcYo2OMLizszN	NX3T[4x{OSCq		MWTy[ZNkfWW\|IFLBNVQ2KG2nZHnheIVlKGGyb4D0c5Nqew>?	NH3OR\|M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{m0PFc2OSd-MkO5OFg4PTF:L3G+
HepG2	Ml3CSpVv[3Srb36gRZN{[Xl?	NWrjVHlRPDBizszN	M37q[lYwOTJiaB?=		NXe5O2hbcW6qaXLpeJMhfGinIHnuZ5Jm[XOnIH;mJJAuTVKNMTDhcoQheC2lLVr1ckBxem:2ZXnuJIV5eHKnc4Ppc44h[nliUFy=	M3vpSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OUSyPFUyLz5{M{m0Nlg2OTxxYU6=
HPAF-II	M{nWcmZ2dmO2aX;uJGF{e2G7	M2Cy[\|ExKM7:TdMg	NVzkfY9VPiCq		NWC2c4V[cW6lcnXhd4UhdWmULUG0N{BmgHC{ZYPzbY9v	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzl5M{exNEc,OjN7N{O3NVA9N2F-
BxPC-3	NGXXVpNHfW6ldHnvckBCe3OjeR?=	MmC0NVAh\|ryPwrC=	MnHpOkBp		MX;pcoNz\WG\|ZTDtbXIuOTR\|IHX4dJJme3Orb36=	NUnwSYtZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5O\|M4OTBpPkKzPVc{PzFyPD;hQi=>
COLO205	NWHxXFlbSXCxcITvd4l{KEG\|c3H5	MoHVNVAwOjBxNECg{txO	MnTSNlQhcA>?		NVHvPJhwcW6mdXPld{BFVkFibHHk[IVzKG[xcn3heIlwdg>?	NHvIU3A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NECxPVExQCd-MkSwNVkyODh:L3G+
G292	MkL4RZBweHSxc3nzJGF{e2G7	NWP0VFFJOzEEoN88US=>	MlTGNkBp		NXvadW9yemW\|dH;y[ZMh[2Gyc3HpZ4lvNWmwZIXj[YQh[2WubDDk[YF1cA>?	MoC2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyMUK5N\|AoRjJ2MEGyPVMxRC:jPh?=
SGC7901	Ml7xRZBweHSxc3nzJGF{e2G7	MYCyNOKh\|ryP	MYGxJIg>		NX7wWnd1cW6qaXLpeJMh[XCxcITvd4l{KGmwZIXj[YQh[nliSV\OMe6yyqCjbnSgOgKBui2GRmXS	MnTBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyMke3OVAoRjJ2MEK3O\|UxRC:jPh?=
MGC803	Ml;HRZBweHSxc3nzJGF{e2G7	NY\jUWhkOjEEoN88US=>	NGjCTZQyKGh?		M2GyRolvcGmkaYTzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KEmITj5OteKh[W6mIEZihNIuTE[XUh?=	MmLIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyMke3OVAoRjJ2MEK3O\|UxRC:jPh?=
HPMC	Mlj0RZBweHSxc3nzJGF{e2G7	MYixNOKh\|ryP	NFT2b3EzPMLiaB?=		NUjrTGZbemW4ZYLz[ZMh\GWlcnXhd4UhcW5iY3XscEB3cWGkaXzpeJkhcW6mdXPl[EBjgSCKR2DEVy=>	M3jCZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MESyPFM5Lz5{NEC0Nlg{QDxxYU6=
HCT-8	NViw[Y1DSXCxcITvd4l{KEG\|c3H5	NHfVXVkyOMLizszN	NH\ZelczPMLiaB?=		M{nSU4Rm[3KnYYPld{Bk\WyuIHHwc5B1d3OrczDpcoR2[2WmIHL5JFUuTlV?	NFXDOHk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC5OVg3Oyd-MkSwPVU5PjN:L3G+
HPMC	MUPGeY5kfGmxbjDBd5NigQ>?	MWmxNOKh\|ryP	M2rZVFQ5KGh?		MWry[ZZmenOnczD0bIUh[2ijbnfld{BqdiClZXzsJI1wenCqb3zv[5khcW6mdXPl[EBjgSCKR2DEVy=>	MnzzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyNEK4N\|goRjJ2MESyPFM5RC:jPh?=
A549	MX3GeY5kfGmxbjDBd5NigQ>?	MYC1NOKh\|ryP	MU[yJIg>		MVzicI9kc3NiRWLLJJBpd3OyaH;yfYxifGmxbjDt[YRq[XSnZDDifUAyNDJvTmG=	Ml;KQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyNke3NlcoRjJ2ME[3O\|I4RC:jPh?=
Caco-2	M1zpc2Fxd3C2b4Ppd{BCe3OjeR?=	NYizToN5OTEEoN88US=>	NITkXXozPMLiaB?=		NIXmbmZl\WO{ZXHz[ZMh[2WubDDhdI9xfG:\|aYOgbY5lfWOnZDDifUA2NU[X	NGDOToE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC5OVg3Oyd-MkSwPVU5PjN:L3G+
AGS	MVzGeY5kfGmxbjDBd5NigQ>?	MVOxNEDPxE4EoB?=	M{nqVVAvPSCq		M3T0O4lvcGmkaYTzJJRp\SC3cILl[5Vt[XSrb36gc4YhfGinIFnMMVgh\2WwZR?=	NWLNNGd5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxNFYyPjZpPkK0NVA3OTZ4PD;hQi=>
Ca9-22	MkXWSpVv[3Srb36gRZN{[Xl?	Mnq2N{DPxE1?	Mmf0NU8zKGh?		MW\y[YR2[2W\|IFjiVk1qdmS3Y3XkJGFVTi1{IIDoc5NxcG:{eXzheIlwdg>?	NFvrdYU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEGyOlU{Oid-MkSxNlY2OzJ:L3G+
Ca9-22	M3zWe2Z2dmO2aX;uJGF{e2G7	NXjaepVGOyEQvF2=	NVn5e4NsOSCq		MULhZo9tcXOqZYOgeIhmKGGkaXzpeJkhd2ZiSHLSJJRwKGmwZIXj[UBKVC16IIDyc4R2[3Srb36=	NUnoXGQ3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxNlY2OzJpPkK0NVI3PTN{PD;hQi=>
HAECs	M2fHemZ2dmO2aX;uJGF{e2G7	MlriNVAh\|ryP	NYjIdnRVOSCq		NXW3UHc2yqCjdITlcpVifGW\|IGTOSk3PuS2\|dHnteYxifGWmIFnDRW0uOSCjbnSgWmNCVS1zIHX4dJJme3Orb36=	MlfFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzM{S2OVcoRjJ2MUO0OlU4RC:jPh?=
Caco-2	MVTGeY5kfGmxbjDBd5NigQ>?	NIjEbYo2OMLizszN	NF7nWFg1QGh?	M{nlW2ROW09?	MUTlcohidmOnczD0bIUhdVKQQTDs[ZZmdHNib3dCpHNEVk5zQTzGXHlFOy{EoFzDWEzDqEyRWD\|CpGhKTjODLNMgXmcyPi{EoGDESVZCyqCjbnVCpGxISUyVMUdCpIdmdmW\|wrDjc{11emWjdHXkJJdqfGhiRHX4	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF4MU[5OUc,OjRzNkG2PVU9N2F-
MCF-7	Mny1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEnOfWgyOCEQvF2=	NUnCR5ZiPDiq	M3jBd2ROW09?	NILY[VVz\X[ncoPld{BDVkZvaX7keYNm\CClZXzsJIN6[2ynIHHydoV{fA>?	MmDJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzNkO0NFQoRjJ2MU[zOFA1RC:jPh?=
SMMC7721	MlvjSpVv[3Srb36gRZN{[Xl?	NUnKTmlMOjVxNUCg{txO	MU[yOEBp		MX7zeZBxemW\|c3XzJJRp\SCneIDy[ZN{cW:wIH;mJJAuSWu2IH;yJJAuTVKNMT:yxsA>	NVraRnJbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxOlgxPTZpPkK0NVY5ODV4PD;hQi=>
SGC7901	MUjBdI9xfG:\|aYOgRZN{[Xl?	NH3TZ3c2OMLizszN	M3XqT\|I1NzR6L{eyJIg>	NI[4Z5dFVVOR	NHLYT5JqdmS3Y3XzJIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIFrBT\|Ihe2iUTlG=	M1fDO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUe4NlQxLz5{NEG3PFI1ODxxYU6=
7721	M1zRfmFxd3C2b4Ppd{BCe3OjeR?=	NHf1O5k{OCEQvF2=	NWLW[FdPPSCm		MYXk[YNz\WG\|ZYOgZ4VtdCCycn;sbYZmemG2aX;u	NXjjR4R6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyNVEzPTNpPkK0NlEyOjV\|PD;hQi=>
DLD-1	M3PabWZ2dmO2aX;uJGF{e2G7	MWWyNOKh\|ryP	NIjMNGE1QCCq		NVPyVXJlemWmdXPld{B1cGViQl7JVFMh\XiycnXzd4lwdiCycnWteJJm[XSnZDD3bZRpKDVvYYrhMYRE	NEHKN5Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEKxNVU5OSd-MkSyNVE2QDF:L3G+
HT-29	Ml\3SpVv[3Srb36gRZN{[Xl?	MV2yNOKh\|ryP	MX20PEBp		NFfSOXFz\WS3Y3XzJJRp\SCETlnQN{BmgHC{ZYPzbY9vKHC{ZT30doVifGWmIIfpeIghPS2jenGt[GM>	M2fWb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkGxOVgyLz5{NEKxNVU5OTxxYU6=
7402	M1TKWGFxd3C2b4Ppd{BCe3OjeR?=	MYCzNEDPxE1?	MW[1JIQ>		NWi4bGhp\GWlcnXhd4V{KGOnbHygdJJwdGmoZYLheIlwdg>?	NETkOYk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEKxNVI2Oyd-MkSyNVEzPTN:L3G+
MCF-7	MnHKSpVv[3Srb36gRZN{[Xl?	M1rW[lIxKM7:TR?=	NGjLR3UyKGh?		NYPHO3NV[WKxbHnzbIV{KGW6cILld5Nqd25ib3[gdIhwe3Cqb4L5cIF1\WRiRWLLJINwNXS{ZXH0cYVvfCC5aYToJINwdmq3Z3H0[S=>	NFjvUWo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEKxOlI5QSd-MkSyNVYzQDl:L3G+
MCF-7	M3HkWGFxd3C2b4Ppd{BCe3OjeR?=	MlzMNlAh\|ryP	M1[yNVEhcA>?		NXTCUlRFcW6lcnXhd4V{KGOjc4Dhd4UuQSCnbor5cYUh[WO2aY\peJk>	NHm0cYk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEKxOlI5QSd-MkSyNVYzQDl:L3G+
CRL-2302	M1H6UmZ2dmO2aX;uJGF{e2G7	MnfINlAh\|ryP	NHrDSW4xNjViaB?=		MkC3bY5pcWKrdIOgRZBmdGmwLXnu[JVk\WRicHjvd5Bpd3K7bHH0bY9vKG:oIFXyb{BidmRiQXv0	NIrzVlQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEKyO\|kyQCd-MkSyNlc6OTh:L3G+
ARPE-19	NWOxbllqTnWwY4Tpc44hSXO\|YYm=	M2PWdVIxKM7:TR?=	NXjIU4FzOC53IHi=		NYm4bm9CcW6qaXLpeJMhSXCnbHnuMYlv\HWlZXSgdIhwe3Cqb4L5cIF1cW:wIH;mJGVzcyCjbnSgRYt1	Mk\FQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{Mke5NVgoRjJ2MkK3PVE5RC:jPh?=
MG-63	MoHBSpVv[3Srb36gRZN{[Xl?	M4PpbVIxKM7:TR?=	MoXnNE42KGh?		NGjDcWljdG:la4OgeIhmKEOKLXnu[JVk\WRicHjvd5Bpd3K7bHH0[YQhTUyNMTDwdo91\WmwIHX4dJJme3Orb36=	NHTiTXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEKzPVY1OCd-MkSyN\|k3PDB:L3G+
SGC-7901	M1z2OGFxd3C2b4Ppd{BCe3OjeR?=	M{fFTFIxKM7:TR?=	NXP2TGNFOjRiaB?=		NGHqbVVqdmirYnn0d{BEWC2vZXTpZZRm\CCjcH;weI9{cXN?	M4TUc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkSxN\|UyLz5{NEK0NVM2OTxxYU6=
NUGC2	NYOwNWFPTnWwY4Tpc44hSXO\|YYm=	MonOOVAh\|ryP	MWG0PEBp	MlHCSG1UVw>?	NUPjUpc5cW6lcnXhd4V{KGW6cILld5Nqd25ib3[gTGxCNUFyMjDvdkBJVEFvQUK0JI1wdGWldXzldy=>	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ2NECyN{c,OjR{NESwNlM9N2F-
NUGC3	M3\MemZ2dmO2aX;uJGF{e2G7	NEC5[lU2OCEQvF2=	NHq2fVY1QCCq	MWrEUXNQ	NHHzfZRqdmO{ZXHz[ZMh\XiycnXzd4lwdiCxZjDIUGEuSTB{IH;yJGhNSS2DMkSgcY9t\WO3bHXz	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ2NECyN{c,OjR{NESwNlM9N2F-
KATOIII	NH;kTIdHfW6ldHnvckBCe3OjeR?=	NET3Uo42OCEQvF2=	NELTTmM1QCCq	NUL6[GNvTE2VTx?=	NFWxW3hqdmO{ZXHz[ZMh\XiycnXzd4lwdiCxZjDIUGEuSTB{IH;yJGhNSS2DMkSgcY9t\WO3bHXz	NVTRdmdbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyOFQxOjNpPkK0NlQ1ODJ\|PD;hQi=>
NCI-N87	NFX1[mxHfW6ldHnvckBCe3OjeR?=	NH7oO5Q2OCEQvF2=	NG\0OXU1QCCq	MU\EUXNQ	NHjvRpVqdmO{ZXHz[ZMh\XiycnXzd4lwdiCxZjDIUGEuSTB{IH;yJGhNSS2DMkSgcY9t\WO3bHXz	M1\Wc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkS0NFI{Lz5{NEK0OFAzOzxxYU6=
OE19	MlfWSpVv[3Srb36gRZN{[Xl?	Mn3qOVAh\|ryP	NULnfGI{PDhiaB?=	M1HzW2ROW09?	MULpcoNz\WG\|ZYOg[ZhxemW\|c3nvckBw\iCKTFGtRVAzKG:{IFjMRU1COjRibX;s[YN2dGW\|	M1nV[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkS0NFI{Lz5{NEK0OFAzOzxxYU6=
MKN7	MYfGeY5kfGmxbjDBd5NigQ>?	MoXuOVAh\|ryP	NF;BcWU1QCCq	NYPpSJhUTE2VTx?=	MUXpcoNz\WG\|ZYOg[ZhxemW\|c3nvckBw\iCKTFGtRVAzKG:{IFjMRU1COjRibX;s[YN2dGW\|	NF[4XGE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK0OFAzOyd-MkSyOFQxOjN:L3G+
TE4	MWjGeY5kfGmxbjDBd5NigQ>?	NHHF[JI2OCEQvF2=	MYq0PEBp	Mn7ISG1UVw>?	NITPb212eHKnZ4XsZZRmeyC2aHWg[ZhxemW\|c3nvckBw\iCKTFGgZ4xie3NiSR?=	NU\wdZhxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyOFQxOjNpPkK0NlQ1ODJ\|PD;hQi=>
KYSE30	M3\1dWZ2dmO2aX;uJGF{e2G7	MnHTOVAh\|ryP	MnXqOFghcA>?	M2rQXWROW09?	MnjDeZBz\We3bHH0[ZMhfGinIHX4dJJme3Orb36gc4YhUEyDIHPsZZN{KEl?	M3myXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkS0NFI{Lz5{NEK0OFAzOzxxYU6=
TE5	NEHsNWtHfW6ldHnvckBCe3OjeR?=	NG\5cpI2OCEQvF2=	Ml\aOFghcA>?	NYTqPWpJTE2VTx?=	MoWzeZBz\We3bHH0[ZMhfGinIHX4dJJme3Orb36gc4YhUEyDIHPsZZN{KEl?	NXz6WYhWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyOFQxOjNpPkK0NlQ1ODJ\|PD;hQi=>
TE1	M3zIVWZ2dmO2aX;uJGF{e2G7	MXi1NEDPxE1?	NXfsUIpSPDhiaB?=	NF;GcVBFVVOR	MV\1dJJm\3WuYYTld{B1cGViZYjwdoV{e2mxbjDv[kBJVEFiY3zhd5MhUQ>?	M2O3OVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkS0NFI{Lz5{NEK0OFAzOzxxYU6=
TE3	NVm1elJpTnWwY4Tpc44hSXO\|YYm=	M2G1[FUxKM7:TR?=	NIfqd3c1QCCq	M3;GTWROW09?	NYD5V2F[fXC{ZXf1cIF1\XNidHjlJIV5eHKnc4Ppc44hd2ZiSFzBJINt[XO\|IFm=	NX7iUJY4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyOFQxOjNpPkK0NlQ1ODJ\|PD;hQi=>
KYSE30	NXPTSoJHTnWwY4Tpc44hSXO\|YYm=	M2D2XVIxNzVyL{GwNEDPxE1?	MnvGOFghcA>?	Mn\jSG1UVw>?	M3joOolvcGmkaYTzJJAuTXKtIHHu[EB4d3K2bXHucolvKGSxd37y[Yd2dGG2ZXSgdE1Cc3RiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ2NECyN{c,OjR{NESwNlM9N2F-
TE1	M2LsOmZ2dmO2aX;uJGF{e2G7	Mkj5NlAwPTBxMUCwJO69VQ>?	M{XZeFQ5KGh?	MnPkSG1UVw>?	MmrjbY5pcWKrdIOgdE1GemtiYX7kJJdwenSvYX7ubY4h\G:5boLl[5Vt[XSnZDDwMWFsfCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	M2f4XFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkS0NFI{Lz5{NEK0OFAzOzxxYU6=
TE4	NFzrVZRHfW6ldHnvckBCe3OjeR?=	NIjuXJczOC93MD:xNFAh\|ryP	MYK0PEBp	Mm\DSG1UVw>?	NWHaTJB[cW6qaXLpeJMheC2HcnugZY5lKHexcoTtZY5vcW5iZH;3cpJm\3WuYYTl[EBxNUGtdDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	MoTkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{NESwNlMoRjJ2MkS0NFI{RC:jPh?=
HT29	M3XIOmZ2dmO2aX;uJGF{e2G7	MnXFNVAh\|ryP	NWHOT2tjOiCq		MlvNbY5pcWKrdIOgc4YhUkGNMjygSXJMOS9{IHHu[EBUXEGWMzDwbI9{eGixconsZZRqd25?	M4fudVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2Mk[1Nlk{Lz5{NEK2OVI6OzxxYU6=
HepG2	M2fNRmFxd3C2b4Ppd{BCe3OjeR?=	MX2yNEDPxE1?	NUDMPFljOjRiaB?=		MXXpcohq[mm2czDFVmsyNzJicHjvd5Bpd3K7bHH0bY9vKGGwZDDlcohidmOnczDWRlEucW6mdXPl[EBieG:ydH;zbZM>	MnPyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{NEe5NFkoRjJ2MkS3PVA6RC:jPh?=
HepG2	M4HFR2Z2dmO2aX;uJGF{e2G7	MUeyNEDPxE1?	MnTjNkBp		MnXu[Y5p[W6lZYOgWmIyNWmwZIXj[YQhTk:[T{PhJJRz[W6\|Y4LpdJRqd26jbDDhZ5Rqfmm2eR?=	NFiwfnU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK0O\|kxQSd-MkSyOFc6ODl:L3G+
MC-3	MWDBdI9xfG:\|aYOgRZN{[Xl?	Mm\qNVAh\|ryP	M4TTelI1KGh?		NFm2TYxxd3SnboTpZZRm\CCPRWPDMYlv\HWlZXSgZZBweHSxc3nzJIlvKCClZXzsdy=>	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ5MEWyN{c,OjR{N{C1NlM9N2F-
Raji	NV7r[21QTnWwY4Tpc44hSXO\|YYm=	NWXCXoY5OTBizszN	NEHyS\|gyKGh?		M2XLXYJtd2OtczDod2JCTkZiaX7keYNm\CCHcnuxM\|IheGixc4Doc5J6dGG2aX;u	NG\NT3I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK2PVY{OCd-MkSyOlk3OzB:L3G+
Raji	NWHlSIZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV61PJE4OTBizszN	M1ntd\|EhcA>?		NGfvdIhqdmirYnn0d{B1cGViYnHzZYwhd3JiaIPCRWZHNXO2aX31cIF1\WRiY3XscEBxem:uaX\ldoF1cW:wIHHu[EB3cWGkaXzpeJk>	NWnucnZiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyOlk3OzBpPkK0NlY6PjNyPD;hQi=>
A549	M2fLU2Z2dmO2aX;uJGF{e2G7	NVn2XpZ5OzBizszN	NEDTS2IxNjViaB?=	M{Ox[mROW09?	M3WySolvcGmkaYTzJJRpem:vYnnuMYlv\HWlZXSgR{9GSlEQsjDUbJIzOzYEoIDoc5NxcG:{eXzheIlwdg>?	M{DR[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2Mke3Olk3Lz5{NEK3O\|Y6PjxxYU6=
HCSMCs	NV7tNnZyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3i4SFExKM7:TR?=	MVKyOEBp		M3T1SoJtd2OtczDGRWJRPC2rbnT1Z4VlKEiFQWPNR{Bxem:uaX\ldoF1cW:w	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDNzMkO4NUc,OjR\|MUKzPFE9N2F-
PANC-1	Ml7KSpVv[3Srb36gRZN{[Xl?	Mm\6NlAh\|ryP	M{SzXlQ5KGh?		MnPibY5pcWKrdIOgeIhmKGW6cILld5Nqd25ib3[g{rQ3TCCrbjDy[ZNxd26\|ZTD0c{B1cGViUGDBVu61yqCjZ3;ubZN1yqB?	NVzNUGJNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyPVQyOzNpPkK0Nlk1OTN\|PD;hQi=>
A549	M4HDVWZ2dmO2aX;uJGF{e2G7	MlH3N\|Ah\|ryP	MV6wMlUhcA>?	MVrEUXNQ	Mn\pbY5pcWKrdIOgeIhmKHSqcn;tZolvNWmwZIXj[YQhUUxvOD;DXGNNQC2OdXOgZYN1cX[rdIm=	NX3ibHpERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyO\|c3QTZpPkK0Nlc4Pjl4PD;hQi=>
SW480	NEXJfFVHfW6ldHnvckBCe3OjeR?=	M1XwcFExKM7:TR?=	NYXzV3A5OjBiaB?=	NVzKfpk3TE2VTx?=	NYfwVHBse3WycILld5NmeyC2aHWgR3JVKGGldHn2bZR6	MlPtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR\|MkSzOlYoRjJ2M{K0N\|Y3RC:jPh?=
HEK 293	MWHGeY5kfGmxbjDBd5NigQ>?	NYnscplYOTBizszN	NV[4SG1qPSCq	Mo\sSG1UVw>?	MXHpcohq[mm2czDXcpQucW6mdXPl[EDPui2lYYTlcolvN1SFRkSgZYN1cX[rdImgZY5lKG63Y3zlZZIh\|rJvY3H0[Y5qdiCjY3P1cZVt[XSrb36=	NF\uWVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEOyOFM3Pid-MkSzNlQ{PjZ:L3G+
HEK 293	MWPGeY5kfGmxbjDBd5NigQ>?	MVuxNEDPxE1?	M{W0dFUhcA>?	Ml:3SG1UVw>?	NH7UfFF{fXCycnXzd4V{KHSqZTDDVnQh[WO2aY\peJk>	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN{NEO2Okc,OjR\|MkSzOlY9N2F-
HL-60	Mlz6SpVv[3Srb36gRZN{[Xl?	NYnDZms4OTBxMkCg{txO	M4DlTlEhcA>?		M1nwXYlvcGmkaYTzJJRp\cLiTj6gZ4hqdmWwc3nz[Zh1emGldNMgbY5lfWOnZDDkbYZn\XKnboTpZZRqd25iaX70c{BoemGwdXzvZ5l1\XN?	MoPkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR\|NUewNlAoRjJ2M{W3NFIxRC:jPh?=
HL-60	NXn5eZVZTnWwY4Tpc44hSXO\|YYm=	NW\sZWoxOiEEtV2=	M2nBXlE3KGh?	M3u1VWROW09?	NHjaeZlqdmirYnn0d{B1cGViYYPzc4Nq[XSrb36gc4YheFN4MkGgVoFnNTFiYX7kJG5HSVSlMzygZY5lKHSqZTDSRU1qdmS3Y3XkJJBpd3OyaH;yfYxifGmxbjDv[kBvfWOuZXHyJG5HSVSlMx?=	M3TLT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{OwNFY5Lz5{NEOzNFA3QDxxYU6=
HeLa	NGiwPHhHfW6ldHnvckBCe3OjeR?=	M1Lvc\|UxKM7:TR?=	MWWwMlUhcA>?		MlrFZoxw[2u\|IGTSXE0yKG63Y3zlZZIhdWmpcnH0bY9vKGGwZDDUXG5KWCCmb4fuMZJm\3WuYYTpc44>	NEHFSVg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEO3OlgzPyd-MkSzO\|Y5Ojd:L3G+
HUVECs	NXPr[WgyTnWwY4Tpc44hSXO\|YYm=	NGfwNJoyOMLizszN	MUCxJIg>		M2n5[YlvcGmkaYTzJJRp\SCKRFygdoVlfWOnZDDDU3guOiCneIDy[ZN{cW:wIHHu[EBRT0lvMjDy[Yxm[XOn	NXfPOY95RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzPFUyODlpPkK0N\|g2OTB7PD;hQi=>
MCF-7	MoXSSpVv[3Srb36gRZN{[Xl?	NEDQZVEyOMLizszN	M1XVdFExNzNyIH3pci=>		MUny[YR2[2W\|IITo[UBWXFBvZHXw[Y5l\W62IFXST{BxcG:\|cHjvdplt[XSrb36=	M4\WZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{mwPFE6Lz5{NEO5NFgyQTxxYU6=
HGC-27	MVzBdI9xfG:\|aYOgRZN{[Xl?	M2\pTFEhyrWP	NYHpSXhOOSCq		M1jFfZN2eHC{ZYPz[ZMhWkGGMECxJJBtfXNiTVutNlIxPi2rbnT1Z4VlKGOnbHygeoli[mmuaYT5JIxwe3N?	NI\XfpE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESxOlM1QSd-MkS0NVY{PDl:L3G+
PC3	M4W1c2Fxd3C2b4Ppd{BCe3OjeR?=	MV21NEDPxE1?	MmryNE42KGh?		NYPkfYszcW6qaXLpeJMhVUi\LUS0PU1qdmS3Y3XkJIFxd3C2b4Ppd:Kh	NF\6UHQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESyOFg5QSd-MkS0NlQ5QDl:L3G+
HPAEpiCs	NH;JToVHfW6ldHnvckBCe3OjeR?=	NF;i[4E{OCEQvF2=	MUKxJIg>		MmTDbY5pcWKrdIOgWG5HNc7zIIP0bY12dGG2ZXSgdFQzN3B2NDDNRXBMKHCqb4PwbI9zgWyjdHnvci=>	M1jReVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NESxPFcxLz5{NES0NVg4ODxxYU6=
BeWo	M4Dp[mZ2dmO2aX;uJGF{e2G7	MlniNVDDqM7:TR?=	MknMNkBp		NYfOSWRucW6qaXLpeJMhTVKNMT:y	MnTaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2M{O4OFYoRjJ2NEOzPFQ3RC:jPh?=
A498	MlzaRZBweHSxc3nzJGF{e2G7	MnXCOVDDqM7:TR?=	NGfKe3gzPCCq		NWTjbnNKeG:2ZX70bYF1\XQEoITo[UBxem9vYYDvdJRwfGmlIHXm[oVkfHNib3[gUmM>	NHnRWWk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEWwPFQ4Pid-MkS1NFg1PzZ:L3G+
NHBE	NILYWIxHfW6ldHnvckBCe3OjeR?=	MlTTNk8zOCEQvF2=	MmCwNkBp		MWjheJRmdnWjdHXzJGlNNTN\|IIP0bY12dGG2ZXSgR3hEVDhxSVytPEB{\WO{ZYTpc44>	MmDzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2N{m1NlYoRjJ2NEe5OVI3RC:jPh?=
A375	NGK4S4xE\WyuIFnueoF{cW:wIFHzd4F6	NXrFVFlUOTEkgKOyNEDDvU1?	NVy5NYg{OjRiaB?=		M3K5TZJm\HWlZYOgcYVt[W6xbXGgZ4VtdCCrbo\hd4lwdg>?	M1PZO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NE[2NFM3Lz5{NES2OlA{PjxxYU6=
HBMEC	M{OwVWZ2dmO2aX;uJGF{e2G7	M{TtNVExKM7:TR?=	NVjwW3U5OSCq		M3m4d4Jtd2OtczDWSWdHNWmwZIXj[YQhTXCqQUKg[ZhxemW\|c3nvci=>	NHmxeZU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NES1PFk5Oid-MkS0OVg6QDJ:L3G+
HCT-15	NF7rRopHfW6ldHnvckBCe3OjeR?=		NVfGPIdIOSCq		MlvsZZR1\W63YYTld{BRT0V{LXnu[JVk\WRicHjvd5Bpd3K7bHH0bY9vKG:oIFXyb:Kh	M{TTUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEOxOFI2Lz5{NUSzNVQzPTxxYU6=
HCT-15	NWjl[nNoSXCxcITvd4l{KEG\|c3H5		M1rtflEhcA>?		NFPPSWti[m:uaYPo[ZMhfGinIIDyc5Rm[3SrdnWg[YZn\WO2czDv[kBRT0V{wrDh[4FqdnO2IHP1doN2dWmwLXnu[JVk\WRiYYDvdJRwe2m\|	M1XV[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEOxOFI2Lz5{NUSzNVQzPTxxYU6=
786-O	NV;xS5BrSXCxcITvd4l{KEG\|c3H5	MUi1NOKh\|ryP	MlHsNlQhcA>?		M1rm[5BwfGWwdHnheIV{yqC2aHWgdJJwNWGyb4D0c5Rq[yCnZn\lZ5R{KG:oIF7D	NUfQUnFoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1NFg1PzZpPkK0OVA5PDd4PD;hQi=>
HepG2	M3PYPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlnwNlAh\|ryP	MmnRNlQhcA>?		NYnVWpVve3WycILld5NmeyCWR1[t{tIyNWmwZIXj[YQh[2WubDDwdo9tcW[ncnH0bY9vKGGwZDDpcpZie2mxbh?=	M{jK[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NU[wOFg5Lz5{NUW2NFQ5QDxxYU6=
SW480	M2WzWWZ2dmO2aX;uJGF{e2G7	M33jTlIxyqEQvF2=	M4PIUVHDqGh?		MnnjdoVlfWOnczD0bIUh\XiycnXzd4lwdiCxZjDBWGY{KHC{b4TlbY4>	NYDvfYlpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0OFc5OTZpPkK1OFQ4QDF4PD;hQi=>
MDA-MB-231	MoD5SpVv[3Srb36gRZN{[Xl?	M2XqUlI2KM7:TR?=	NHzLcJYzNTNiaB?=		MmPU[IVkemWjc3XzJJAuTVKNMT:yJIFv\CCVMUCwRVQh\XiycnXzd4lwdg>?	M{HXVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUW1PFc2Lz5{NUW1OVg4PTxxYU6=
HepG2	NF;NWG9HfW6ldHnvckBCe3OjeR?=	NEPC[28yOCEQvF2=	M3;POlUhcA>?		M1XDV4Jtd2OtczDwbI9{eGixconsZZRm\CCPQWDLd{BqdmS3Y3XkJIJ6KGW6b3flco92eyCWR1[t{tIy	NYDXRoVWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1OlA1QDhpPkK1OVYxPDh6PD;hQi=>
MCF-7	MYPGeY5kfGmxbjDBd5NigQ>?	NIToO3kyOCEQvF2=	NXTURmxmOSCq		MWHpcohq[mm2czDJUE0yQC2nbnjhcoNm\CClZXzsJI1q\3KjdHnvci=>	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd{N{CxNUc,OjV5MkewNVE9N2F-
H1355	MmTGSpVv[3Srb36gRZN{[Xl?	MoftNlUh\|ryP	NEDRSFIyKGh?		NFTwVIFjdHWwdIOgeIhmKEKdYW3QMYlv\HWlZXSgbY5kemWjc3WgbY4heGixc4Doc{1EcGtzIHHu[EBxcG:\|cHjvMWVTUyCneIDy[ZN{cW:w	Mm\TQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NkmxPFEoRjJ3N{[5NVgyRC:jPh?=
PC12	M3zSUmZ2dmO2aX;uJIF{e2G7				MmjXTY5pcWKrdHnvckBw\iCwZYL2[UBoem:5dHig[oFkfG:{LX3l[IlifGWmIF3BVEBscW6jc3WgZYN1cX[rdImgbY4hcHWvYX6gVGMyOiClZXzsd{whUUN3MDC9JFIh\|ryPLh?=	NH3JfXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEC3O\|M3Oyd-MUiwO\|c{PjN:L3G+
HT-29	NGPGO\|FCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NF[4eIU2KGSjeYO=		M13IUWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSGStNlkh[2WubIOgZYZ1\XJiNTDkZZl{KGK7IGfTWFEh[XO\|YYmsJGlEPTBiPTC0JO69VS5?	M3;GTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEe4N\|E3Lz5{NUC3PFMyPjxxYU6=
IEC6	MYfGeY5kfGmxbjDhd5NigQ>?		NInobYs2KG2rboO=		NFeycHZKdmirYnn0bY9vKG:oIF3FT\|EwOiCrbjDyZZQhUUWFNjDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4hTVKNMT:yJIxwd3BicHjvd5Bpd3K7bHH0bY9vKGSxc3XkJFMxKG2rboOgZoVnd3KnIITvJJN1cW23bHH0bY9vKHerdHigNVAmKHOncoXtJIZweiB3IH3pcpMh[nliaX3teY5w[myxdITpcochdWW2aH;kMEBKSzVyIE2gOE4zKM7:TT6=	MmTTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyN{izNVYoRjJ3MEe4N\|E3RC:jPh?=
NG 108-15	MULGeY5kfGmxbjDhd5NigQ>?				MlHJR49v[2WwdILheIlwdiC{ZYH1bZJm\CC2bzDhZo9tcXOqIF3BVGsh[WO2aY\peJkhcW5ibX;1d4UhdmW3cn;icIF{fG:vYTDhcoQhemG2IHfsbY9u[SCqeXLybYQhVkdiMUC4MVE2KGOnbHzzMEBC[3Srdnn0fUA:KDFyIN88UU4>	M{jUZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3NUO3N\|U1Lz5zNUWzO\|M2PDxxYU6=
PC12	Mo\HSpVv[3Srb36gZZN{[Xl?	MlPsNVAhfU1?	NIPkc5M2KGi{cx?=		M3HkVWFkfGm4YYTpc44hd2ZiToLmNk9CWkViaX6gdoF1KFCFMUKgZ4VtdHNiYYPz[ZN{\WRiYYOgTG8uOSCycn;0[YlvKGmwZIXjeIlwdiCjdDCxNEB2VSCjZoTldkA2KGi{czDwdoV1emWjdHXkJJdqfGhiSl7LJIlvcGmkaYTvdkBUWDZyMEGyOUBnd3JiMTDodkBj\W[xcnWgZ49ueG:3bnSgZYRlcXSrb36gZpkhX2W\|dHXyckBjdG:2IHHuZYx6e2m\|	NEjhZ5Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUO0OVY5PSd-MkGzOFU3QDV:L3G+
PC12	MX;GeY5kfGmxbjDhd5NigQ>?	MXKxNEB2VQ>?	MVy1JIhzew>?		M4TRSWFkfGm4YYTpc44hd2ZiToLmNk9CWkViaX6gdoF1KFCFMUKgZ4VtdHNiYYPz[ZN{\WRiYYOgTG8uOSCycn;0[YlvKGmwZIXjeIlwdiCjdDCxNEB2VSCjZoTldkA2KGi{czDwdoV1emWjdHXkJJdqfGhiTVXLNkBqdmirYnn0c5IhXTBzMk[g[o9zKDFiaIKgZoVnd3KnIHPvcZBwfW6mIHHk[Il1cW:wIHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>?	NHX4[HI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUO0OVY5PSd-MkGzOFU3QDV:L3G+
PC12	NETWeoZHfW6ldHnvckBie3OjeR?=	MVqxNEB2VQ>?	M1vHZVUhcHK\|		NWqwdFFQSWO2aY\heIlwdiCxZjDOdoYzN0GURTDpckBz[XRiUFOxNkBk\WyuczDhd5Nme3OnZDDhd{BJVy1zIIDyc5RmcW5iaX7keYN1cW:wIHH0JFExKHWPIHHmeIVzKDViaILzJJBz\XS{ZXH0[YQhf2m2aDDNSWsyKGmwaHnibZRweiCSREm4NFU6KG[xcjCxJIhzKGKnZn;y[UBkd22yb4Xu[EBi\GSrdHnvckBjgSCZZYP0[ZJvKGKub4SgZY5idHm\|aYO=	MmPvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF\|NEW2PFUoRjJzM{S1Olg2RC:jPh?=
HeLa	MXnGeY5kfGmxbjDhd5NigQ>?	MlvVNlAhfU1?	MUmzJIhzew>?		MVjJcohq[mm2aX;uJI9nKEWUS{GvNkBxcG:\|cHjvdplt[XSrb36gbY4hcHWvYX6gTIVN[SClZXzsd{BifCB{MDD1UUBi\nSncjCzJIhzeyCkeTDX[ZN1\XKwIHLsc5R1cW6pIHHuZYx6e2m\|	MnHpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3N{C2NVUoRjJ\|NUewOlE2RC:jPh?=
RD	NWrmOVdreUiWUzDhd5NigQ>?				MnjNdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKGIHPlcIx{	NFr4d4M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
NB1643	MlrsdWhVWyCjc4PhfS=>				NGTWbFdyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTlKxOlQ{KGOnbHzz	MnjRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
RD	NI\LendyUFSVIHHzd4F6				M1fSfpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHJFKGOnbHzz	NW\JcFdmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-MC	MlnMdWhVWyCjc4PhfS=>				NHrvZ\|ZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1OSyClZXzsdy=>	M13sZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
TC32	MWfxTHRUKGG\|c3H5				M4P4[JFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHREOzJiY3XscJM>	NEW3XHA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
MDA-MB-231	MUXGeY5kfGmxbjDhd5NigQ>?	NULtcVhMPTBidV2=			Ml;aSI94dnKnZ4XsZZRqd25ib3[gUW1ROiCrbjDoeY1idiCPRFGtUWIuOjNzIHPlcIx{KGG2IEWwJJVOKGK7IGfld5Rmem5iYnzveEBidmGueYPpdy=>	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjl{NkKyOkc,OjJ7Mk[yNlY9N2F-
MDA-MB-231	NYnvPZJkTnWwY4Tpc44h[XO\|YYm=	NVvBT5I2PTBidV2=			MnfLSI94dnKnZ4XsZZRqd25ib3[gUW1RQSCrbjDoeY1idiCPRFGtUWIuOjNzIHPlcIx{KGG2IEWwJJVOKGK7IGfld5Rmem5iYnzveEBidmGueYPpdy=>	NXXUN5h7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK5NlYzOjZpPkKyPVI3OjJ4PD;hQi=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	c-Jun / α-tubulin / p-ERK / ERK / p-AKT / AKT; PubMed: 17482134 Cancer cell ERK regulates c-Jun levels in melanoma. The indicated melanoma cell lines were treated with 50μM PD98059 (PD) or 10μM LY294002 (LY) for 12h in the absence of serum. Protein samples were analyzed by Western blots using the indicated antibodies. α-Tubulin reveals equal loading. p-JNK / JNK / Cyclin D1 ; PubMed: 17482134 Cancer cell Inhibition of the MEK/ERK pathway affects c-Jun, P-JNK and cyclin D1 levels. The indicated melanoma cell lines were treated with 50μM PD98059 for 16h. Protein samples were analyzed by Western blots using the indicated antibodies. α-Tubulin reveals equal loading. p-HER2 / HER2 ; PubMed: 24244023 J Immunol TE1cells were treated with wortmannin (Akt signal inhibitor), PD98059 (MAPK signal inhibitor), or lapatinib (EGFR and HER2 dual inhibitor) at the indicated doses or with DMSO as a negative control for 48 h. HER2-related signaling molecules were assessed by Western blot. MMP9 / XIAP / VEGF ; PubMed: 29695559 In Vivo SK-Hep1 cells were treated 10 μM PD98059 for 48 h. Protein levels of MMP-9, XIAP, VEGF, cyclin-D1, and pERK were evaluated with western blotting assay.	17482134 24244023 29695559

体内研究

在大脑缺血前30分钟用PD98059处理小鼠可以明显减轻伤害, 使脑梗塞的体积减小^[4]。基于胰腺的湿重和组织学研究发现，提前30分钟用PD98059预处理 (10 mg/kg 静脉注射) 然后每小时注射一次蛙皮素连续三次的小鼠可以明显改善蛙皮素诱导的急性胰腺炎^[7]。卡拉胶损伤一小时后用PD98059 (10 mg/kg) 对小鼠进行治疗可以发现与炎症相关的所有指标均有所下降^[11]。

激酶实验： ^[1]	- 合并体外MEK激酶活性测定: 在含有44-kDa GST-MAPK 或者45-kDa GST-MEK1的体系中检测³²P被掺入蛋白 MBP中的情况。反应体系50 μL ，含有50 mM Tris, pH 7.4/10 mM MgCl₂/2 mM EGTA/10 μM [γ-³²P]ATP，加入10 μg GST-MEK1, 0.5 μg GST-MAPK和 40 μg MBP。30°C 孵育15 分钟, 加入Laemmli SDS 样品缓冲液终止反应。磷酸化的MBP 进行10% SDS-PAGE分析
细胞实验： ^[1]	- 合并 Cell lines: K-Balb, KNRK, v-raf-3Y1, SRA/3Y1, EGFR/3T3, 和K562 Concentrations: 溶于DMSO, 终浓度~100 μM Incubation Time: 3 天, 或者7-10天 Method: 细胞按10,000-20,000个/mL的密度接种在多孔平板中进行单层生长。48小时后把不同浓度的PD98059 加到细胞培养基孵育3天。然后通过胰酶将细胞从平板中消化下来并用Coulter 计数器计数。将细胞按5,000-10,000每皿的浓度接种在35 mm的培养皿中，培养基中含有0.3% 的琼脂和期望浓度的PD98059，让细胞在软琼脂上生长.经过7-10天的生长, 可以借助解剖显微镜将可见的菌落数出来。 (Only for Reference)
动物实验： ^[7]	- 合并 Animal Models: 患有急性胰腺炎的雄性Sprague–Dawley 大鼠 Dosages: 10 mg/kg Administration: 静脉注射 (Only for Reference)

参考文献

- 合并

溶解度 (25°C)

体外	DMSO	14 mg/mL warmed (52.37 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 4% DMSO+30% PEG 300+5% Tween 80+ddH2O	1mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download PD98059 SDF

分子量	267.28
化学式	C₁₆H₁₃NO₃
CAS号	167869-21-8
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
How to formulate this inhibitor for i.p. injection?
回答：
You can prepare the stock by the vehicle 30% PEG400/0.5% Tween80/5% Propylene glycol, 0.5% CMC.

MEK Signaling Pathway Map

MEK Inhibitors with Unique Features

泛MEK抑制剂

U0126-EtOH : MEK1, IC50=0.07 μM; MEK2, IC50=0.06 μM.
活性最高的MEK抑制剂

PD0325901 : MEK, IC50=0.33 nM.
FDA批准的MEK抑制剂

Trametinib (GSK1120212) : Approved by FDA for BRAF V600E mutated metastatic melanoma.
最新的MEK抑制剂

Binimetinib (MEK162, ARRY-162, ARRY-438162) : Potent inhibitor of MEK1/2 with IC50 of 12 nM.

研究领域

产品类型

定制您的化合物库

PD98059

客户使用Selleck生产的PD98059发表文献401篇：

产品安全说明书

MEK抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download PD98059 SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

技术支持

常见问题及建议解决方法

MEK Signaling Pathway Map

MEK Inhibitors with Unique Features

相关MEK产品